1. Home
  2. FNGR vs BYSI Comparison

FNGR vs BYSI Comparison

Compare FNGR & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FingerMotion Inc.

FNGR

FingerMotion Inc.

HOLD

Current Price

$0.47

Market Cap

50.2M

Sector

Technology

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$1.64

Market Cap

58.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNGR
BYSI
Founded
2016
2010
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
58.4M
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
FNGR
BYSI
Price
$0.47
$1.64
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
19.8K
Earning Date
05-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,132,261.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$1.18
52 Week High
$2.35
$3.28

Technical Indicators

Market Signals
Indicator
FNGR
BYSI
Relative Strength Index (RSI) 32.51 50.40
Support Level N/A $1.56
Resistance Level $1.12 $1.83
Average True Range (ATR) 0.11 0.09
MACD -0.02 -0.01
Stochastic Oscillator 7.34 28.57

Price Performance

Historical Comparison
FNGR
BYSI

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: